Shares of CorMedix (CRMD) have gained 21.4% over the past four weeks to close the last trading session at $14.64, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of$19.33 indicates a potential upside of 32%.The average comprises six short-term price targets ranging from a low of $17.00 to a high of$21.00, with a standard deviation of $1.37. While the lowest estimate indicates an ...